A Phase 2 Prospective Interventional Open-Label Multi-Site Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 (OV935) as Adjunctive Therapy in Patients with Rare Epilepsy
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
